New drug combo tested for Tough-to-Treat skin cancer
NCT ID NCT04835805
Summary
This early-stage study is testing a new drug called belvarafenib, both by itself and in combination with other cancer drugs, for people with advanced melanoma that has a specific genetic change (NRAS mutation) and has stopped responding to standard immunotherapy. The main goals are to find safe doses and see if the treatments can shrink tumors. It is for patients whose cancer has gotten worse after prior treatment with drugs like Keytruda or Opdivo.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MELANOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Asan Medical Center - PPDS
Seoul, 05505, South Korea
-
California Pacific Medical Center Research Institute
San Francisco, California, 94115, United States
-
Calvary Mater Newcastle
Waratah, New South Wales, 2298, Australia
-
Charité - Universitätsmedizin Berlin
Berlin, 12203, Germany
-
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
Baltimore, Maryland, 21231, United States
-
Klinikum Mannheim GmbH Universitätsklinikum
Mannheim, 68167, Germany
-
Linear Clinical Research Ltd
Nedlands, Western Australia, 6009, Australia
-
Memorial Sloan Kettering
New York, New York, 10021, United States
-
Ottawa Hospital Regional Cancer Centre
Ottawa, Ontario, K1H 8M2, Canada
-
Peter MacCallum Cancer Centre-East Melbourne
Melbourne, Victoria, 3000, Australia
-
Princess Margaret Hospital
Toronto, Ontario, M5G 2M9, Canada
-
UCSF Helen Diller Family CCC
San Francisco, California, 94158, United States
-
Universitatsklinikum Tubingen
Tübingen, 72076, Germany
-
University of Colorado Cancer Center
Aurora, Colorado, 80045, United States
-
Universitätsklinikum Hamburg-Eppendorf
Hamburg, 20246, Germany
-
Universitätsklinikum Würzburg
Würzburg, 97080, Germany
-
Washington University School of Medicine
St Louis, Missouri, 63110, United States
Conditions
Explore the condition pages connected to this study.